| Date | Title | Description |
| 21.11.2025 | Aspen Neuroscience: $115 Million Series C Raised To Advance Personalized Cell Therapy Pipeline | Aspen Neuroscience has closed a $115 million Series C financing round to accelerate clinical development of its personalized autologous cell therapy programs, marking one of the company’s most significant funding milestones to date. The San... |
| 20.11.2025 | Aspen Neuroscience Raises $115M in Series C Funding | Aspen Neurosciences, a San Diego, CA-based clinical-stage biotechnology company pioneering autologous regenerative therapies, raised $115M in Series C funding.
The round was co-led by OrbiMed, ARCH Venture Partners, Frazier Life Sciences, a... |
| 20.11.2025 | Aspen enriches Parkinson's cell therapy trial with Kite-backed $115M series C | Aspen Neuroscience’s cash reserves have been fertilized with a $115 million series C fundraise that will enrich the biotech’s ongoing trial of a regenerative cell therapy for Parkinson’s disease.
The raise will power Aspen’s phase 1/2 study... |
| 20.11.2025 | Aspen Neuroscience Lands $115M to Accelerate Personalised Parkinson’s Cell Therapy | Aspen Pushes Forward on Personalised Regenerative Medicine
Aspen Neuroscience has closed a $115 million Series C round, calling this financing a turning point. The company says the capital will deepen the clinical progress of ANPD001, widen... |
| 20.11.2025 | Aspen Neuroscience Lands $115M Series C |
SAN DIEGO, CA, Aspen Neuroscience, a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the closing of a $115 million Series C financing round.
>> Click here for more funding data on As... |
| 24.12.2022 | Aspen Neuroscience Receives $40M in Debt Financing From Silicon Valley Bank | Aspen Neuroscience, a San Diego, CA-based private biotechnology company developing autologous cell therapies including an iPSC-derived autologous neuron replacement treatment for Parkinson’s disease (PD), received $40M in Debt Financing.
Si... |
| 09.09.2022 | Meet John Prufeta, General Partner of Medical Excellence Capital | MEC invests in cell therapy, gene therapy, regenerative medicine, synthetic biology, and AI
Venture capital used to be a cottage industry, with very few investing in tomorrow's products and services. Oh, how times have changed! While there ... |
| 16.05.2022 | Digital health news, funding roundup in the prior week; May 16, 2022 | $3.1B to fight COVID globally; Academy partnered with Nuance; Vida launched prescription service
Top Health News
Vida Health, which provides a collaborative care model that provides access to practitioners including coaches, licensed therap... |
| 10.05.2022 | Aspen Neuroscience raises $147.5M | Aspen Neuroscience has raised a $147.5 million Series B co-led by GV, LYFE Capital and Revelation Partners. San Diego-based Aspen is developing cell replacement therapies designed to target neurodegenerative diseases such as Parkinson's dis... |
| 09.05.2022 | Investors take root in Aspen Neuroscience's customized cell therapy as $147.5M round closes | Aspen Neuroscience, a biotech developing the first autologous neuron replacement for Parkinson’s disease, is seeing double, as investors have flooded the company's series B with $147.5 million following an initial $70 million round two year... |
| 09.05.2022 | Aspen Neuroscience Raises $147.5M in Series B Financing | Damien McDevitt, PhD, president and CEO of Aspen Neuroscience, Inc.
Aspen Neuroscience, Inc., a San Diego, CA-based private biotechnology company developing autologous cell therapies, including the first iPSC-derived autologous neuron repla... |
| 09.05.2022 |
Aspen Neuroscience Scores $147.5M More
| San Diego-based biotech startup Aspen Neuroscience said this morning that it has raised $147.5M in a Series B funding round. The company--which is working on treatments for Parkinson's disease--said the funding was co-led by GV, LYFE Capita... |
| 09.05.2022 | San Diego’s Aspen Neuroscience lands $147M for Parkinson’s cell therapy | Aspen Neuroscience, a San Diego biotech that’s developing cell replacement therapy to treat Parkinson’s disease, has raised $147.5 million in a second round of venture capital funding.
The investment brings the total amount raised by Aspen,... |
| 05.05.2021 | Aspen Neuroscience Announces Promotion of Andres Bratt-Leal, PhD, to Senior Vice President of Research & Development | |
| 14.04.2020 | Aspen Neuroscience has announced a $70 Million Series A round to help fund clinical trials for their compounds aimed at treating Parkinson's Disease. | - |
| 09.04.2020 | Funding roundup: At-home medical exams and a Parkinson’s treatment | Read more about the companies that recently raised funding:
Tyto Care
Funding amount: $50 million
Headquarters: New York, Israel
Tyto Care, a company that lets people conduct at-home medical exams, already saw rising demand before the Covid... |
| 03.04.2020 | Aspen Neuroscience Raises $70 Million Led By OrbiMed | Aspen Neuroscience, a biotechnology company developing the first autologous neuron replacement therapy for treating Parkinson’s announced it raised $70 million
Aspen Neuroscience, a biotechnology company developing the first autologous neur... |
| 01.04.2020 | Aspen Neuroscience Announces $70 Million Series A Financing Led by OrbiMed to Advance Development of the First Autologous Neuron Replacement Therapy to Treat Parkinson Disease | - |
| 01.04.2020 | Aspen Neuroscience raises $70M for its experimental Parkinson’s Disease treatment | Since 2012, Dr. Jeanne Loring, the founder of the eponymous Loring Lab at Scripps Research, has been thinking about how to use pluripotent stem cells as a potential treatment for Parkinson Disease.
Now, eight years later, Aspen Neuroscience... |
| 01.04.2020 |
Aspen Neuroscience Gets $70M
| San Diego-based Aspen Neuroscience, a biotechnology company developing treatments for Parkinson disease, said it has raised $70M in a Series A funding round. The funding was led by OrbiMed, and also included ARCH Venture Partners, Frazier H... |
| 01.04.2020 | Aspen Neuroscience Scores $70M Series A |
SAN DIEGO, CA, Aspen Neuroscience announced the close of its Series A funding round of $70 million led by OrbiMed.
>> Click here for more funding data on Aspen Neuroscience
>> To export Aspen Neuroscience funding data to PDF... |
| 01.04.2020 | Aspen Neuroscience Raises $70M in Series A Financing | Aspen Neuroscience, a San Diego, CA-based biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson disease, closed a $70m Series A funding round.
The round was led by OrbiMed with participation fro... |
| 12.12.2019 | Aspen Neuroscience Raises $6.5M in Seed Funding | Aspen Neuroscience Inc., a San Diego, CA-based development stage, private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the ... |
| 12.12.2019 | Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson’s Disease | |
| 12.12.2019 | Aspen Neuroscience launches with $6.5M seed funding to develop personalized and autologous cell therapy for Parkinson’s disease | Parkinson’s disease is characterized by the loss of specific brain cells that make the chemical dopamine. Without dopamine, nerve cells cannot communicate with muscles and people are left with debilitating motor problems. Aspen is focusing ... |
| - | Funding roundup: At-home medical exams and a Parkinson’s treatment | Tyto Care’s kit includes a connected otoscope among other things
Numerous startups offering telehealth or remote monitoring solutions closed funding rounds this week, despite slowing activity due to the Covid-19 pandemic. One of them is Tyt... |
| - | Aspen Neuroscience | “Aspen Neuroscience leverages stem cell biology and genomics for Parkinson disease.” |
| - | Aspen Neuroscience | “Aspen Neuroscience leverages stem cell biology and genomics for Parkinson’s disease.” |
| - | Aiming to treat Parkinson’s by replacing neurons, Aspen Neuroscience nabs $147M | Parkinson’s disease patients lack sufficient amounts of a neurotransmitter that plays a key role in the brain’s ability to control movement and motor coordination. While drugs are available to address this deficiency, their effectiveness wa... |
